Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RLAY · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
29
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Relay Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
RLAY insider buying and selling by quarter
RLAY insider selling · RLAY insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · RLAY ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RLAY executive sell shares · RLAY board member insider trading · RLAY insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 14, 2026 | Catinazzo Thomas CFO | Sale | 17,717 | $228K | Form 4 |
| Apr 28, 2026 | Catinazzo Thomas CFO | Sale | 972 | $14K | Form 4 |
| Apr 28, 2026 | Rahmer Peter See remarks | Sale | 753 | $11K | Form 4 |
| Apr 28, 2026 | Bergstrom Donald A President, R&D | Sale | 1,490 | $22K | Form 4 |
| Apr 9, 2026 | Catinazzo Thomas CFO | Option | 1,800 | $9K | Form 4 |
| Apr 7, 2026 | Catinazzo Thomas CFO | Sale | 17,717 | $230K | Form 4 |
| Apr 9, 2026 | Catinazzo Thomas CFO | Sale | 1,800 | $27K | Form 4 |
| Mar 9, 2026 | Catinazzo Thomas CFO | Sale | 17,717 | $178K | Form 4 |
| Jan 27, 2026 | Bergstrom Donald A President, R&D | Sale | 18,895 | $144K | Form 4 |
| Jan 28, 2026 | Bergstrom Donald A President, R&D | Sale | 2,686 | $23K | Form 4 |
| Dec 31, 2025 | Rahmer Peter See remarks | Award | 994 | $3K | Form 4 |
| Jan 27, 2026 | Rahmer Peter See remarks | Sale | 11,684 | $89K | Form 4 |
| Jan 28, 2026 | Rahmer Peter See remarks | Sale | 1,354 | $11K | Form 4 |
| Jan 27, 2026 | Catinazzo Thomas CFO | Sale | 13,820 | $105K | Form 4 |
| Jan 28, 2026 | Catinazzo Thomas CFO | Sale | 1,695 | $14K | Form 4 |
| Dec 31, 2025 | Patel Sanjiv President and CEO · Director | Award | 994 | $3K | Form 4 |
| Jan 6, 2026 | Patel Sanjiv President and CEO · Director | Sale | 43,168 | $338K | Form 4 |
| Nov 3, 2025 | Patel Sanjiv President and CEO · Director | Sale | 62,073 | $435K | Form 4 |
| Oct 28, 2025 | Rahmer Peter See remarks | Sale | 19,135 | $139K | Form 4 |
| Oct 29, 2025 | Rahmer Peter See remarks | Sale | 21,394 | $160K | Form 4 |
| Oct 28, 2025 | Catinazzo Thomas CFO | Sale | 21,664 | $158K | Form 4 |
| Oct 28, 2025 | Bergstrom Donald A President, R&D | Sale | 30,897 | $225K | Form 4 |
| Jul 28, 2025 | Rahmer Peter See remarks | Sale | 1,359 | $5K | Form 4 |
| Jul 29, 2025 | Rahmer Peter See remarks | Sale | 15,724 | $58K | Form 4 |
| Jul 28, 2025 | Catinazzo Thomas CFO | Sale | 1,701 | $6K | Form 4 |
Bergstrom Donald A
President, R&D
Date
Jan 27
Shares
18,895
Price
$7.62
Value
$144K
Patel Sanjiv
President and CEO · Director
Date
Dec 31
Shares
994
Price
$2.99
Value
$3K
Patel Sanjiv
President and CEO · Director
Date
Jan 6
Shares
43,168
Price
$7.82
Value
$338K
Patel Sanjiv
President and CEO · Director
Date
Nov 3
Shares
62,073
Price
$7.00
Value
$435K
Bergstrom Donald A
President, R&D
Date
Oct 28
Shares
30,897
Price
$7.29
Value
$225K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RLAY insider trading
RLAY insider trades
Relay Therapeutics, Inc. (RLAY) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Catinazzo Thomas (CFO), Rahmer Peter (See remarks), Bergstrom Donald A (President, R&D). Over the past 12 months, 5 insiders have filed transactions with the SEC. RLAY insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Relay Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RLAY insider trading · 5 questionsThe insiders of Relay Therapeutics, Inc. (RLAY) include executives and directors such as Catinazzo Thomas (CFO), Rahmer Peter (See remarks), Bergstrom Donald A (President, R&D), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026